Claims
- 1. A compound of the formula ##STR38## wherein: one of R.sub.1 and R.sub.2 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl or R.sub.1 and R.sub.2 together are C.sub.2-5 polymethylene; and R'.sub.4 is ethyl, isopropyl, t-butyl or cyclopentyl.
- 2. The compound according to claim 1, wherein R'.sub.4 is ethyl.
- 3. The compound according to claim 1, which is 6-t-butyl-3,4-epoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran.
- 4. The compound according to claim 1, which is trans-7-(i-propyl)-3,4-epoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran.
- 5. The compound according to claim 1, which is 3,4-epoxy-6-ethyl-3,4-dihydro-2H-1-benzopyran.
- 6. The compound according to claim 1, which is 3,4-epoxy-3,4-dihydro-2,2-dimethyl-6-cyclopentyl-2H-1-benzopyran.
Priority Claims (2)
| Number |
Date |
Country |
Kind |
| 8610911 |
May 1986 |
GBX |
|
| 8623768 |
Oct 1986 |
GBX |
|
Parent Case Info
This is a divisional of our application Ser. No. 045,626, filed May 1, 1987, now U.S. Pat. No. 4,943,582, issued July 24, 1990.
The present invention relates to novel benzopyrans having pharmacological activity, to a process and intermediates for preparing them, to pharmaceutical compositions containing them, and to their use in the treatment of mammals.
European Patent Publications 76075, 93535, 95316, 107423, 120427, 126311, 126350, 126367 and 138134 disclose classes of compounds that are described as having blood pressure lowering activity or anti-hypertensive activity.
A class of compounds has now been discovered which are 4-substituted benzopyrans substituted in the 6-position by an alkyl group. In addition, such benzopyrans have been found to have blood pressure lowering activity, useful in the treatment of hypertension. In addition, these compounds are believed to be K.sup.+ channel activators which indicates that they are of potential use in the treatment of disorders associated with smooth muscle contraction of the gastro-intestinal tract, respiratory system, uterus or urinary tract. Such disorders include irritable bowel syndrome and diverticular disease, reversible airways obstruction and asthma; premature labour; and incontinence. They are also indicated as of potential use in the treatment of cardiovascular disorders other than hypertension, such as congestive heart failure, angina, peripheral vascular disease and cerebral vascular disease.
Accordingly, the present invention provides a compound of formula (I) or, when the compound of formula (I) contains a salifiable group, a pharmaceutically acceptable salt thereof: ##STR2## wherein:
Y is N or (when R.sub.3 is hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy) CH;
one of R.sub.1 and R.sub.2 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl or R.sub.1 and R.sub.2 together are C.sub.2-5 -polymethylene;
R.sub.3 is hydrogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy;
R.sub.4 is a C.sub.3-8 cycloalkyl group or a C.sub.1-6 alkyl group optionally substituted by a group R.sub.7 which is hydroxy, C.sub.1-6 alkoxy, amino optionally substituted by one or two C.sub.1-6 alkyl groups; C.sub.1-7 alkanoylamino, C.sub.3-8 -cycloalkyloxy, C.sub.3-8 cycloalkylamino, or 1,3-dioxo-2-isoindoline;
When Y is N, R.sub.5 is hydrogen, C.sub.1-6 alkyl optionally substituted by halogen, hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, carboxy or amino optionally substituted by one or two independent C.sub.1-6 alkyl groups, or C.sub.2-6 alkenyl, amino optionally substituted by a C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl or C.sub.1-6 alkenyl group or by a C.sub.1-6 alkanoyl group optionally substituted by up to three halo atoms, by a phenyl group optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen, or aryl or heteroaryl, either being optionally substituted by one or more groups or atoms selected from the class of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halogen, trifluoromethyl, nitro, cyano, C.sub.1-12 carboxylic acyl, or amino or aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups and R.sub.6 is hydrogen or C.sub.1-6 alkyl, or R.sub.5 and R.sub.6 together are --CH.sub.2 --(CH.sub.2).sub.n --Z--(CH.sub.2).sub.m -- wherein m and n are 0 to 2 such that m+n is 1 or 2 and Z is CH.sub.2, O, S or NR wherein R is hydrogen, C.sub.1-9 alkyl, C.sub.2-7 alkanoyl, phenyl C.sub.1-4 -alkyl, naphthylcarbonyl, phenylcarbonyl or benzyl-carbonyl optionally substituted in the phenyl or naphthyl ring by one or two of C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; mono-or bi-cyclic-heteroarylcarbonyl;
When Y is CH, R.sub.5 is NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are independently C.sub.1-6 alkyl, R.sub.8 is hydrogen and R.sub.9 is C.sub.1-6 alkyl or R.sub.8 and R.sub.9 together are C.sub.4-5 polymethylene; or R.sub.6 and R.sub.8 together are --(CH.sub.2).sub.p -- wherein p is 2 or 3, and R.sub.9 is hydrogen or C.sub.1-6 alkyl; or R.sub.5 is CH.sub.2 R.sub.10 wherein R.sub.10 is hydrogen or C.sub.1-5 alkyl; or R.sub.6 and R.sub.10 are --(CH.sub.2).sub.q -- wherein q is 2 or 3;
X is oxygen or sulphur; or
R.sub.5, R.sub.6, X and Y (when N) together are tetrahydroisoquinolinone or tetrahydroisoquinolinthione, optionally substituted in the phenyl ring as defined for R above; the nitrogen-containing group in the 4-position being trans to the R.sub.3 group when R.sub.3 is hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy.
Y is preferably N.
Preferably, R.sub.1 and R.sub.2 are both C.sub.1-4 alkyl, in particular both methyl.
When R.sub.3 is C.sub.1-6 alkoxy, preferred examples of R.sub.3 include methoxy and ethoxy, of which methoxy is more preferred. When R.sub.3 is C.sub.1-7 acyloxy a preferred class of R.sub.3 is unsubstituted carboxylic acyloxy, such as unsubstituted aliphatic acyloxy. However, it is more preferred that R.sub.3 is hydroxy.
Examples of R.sub.4 include cyclopropyl, cyclobutyl, cyclopentyl, cyclonhexyl, cycloheptyl, methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl, optionally substituted by a group R.sub.7.sup.1 which is hydroxy, C.sub.1-4 alkoxy, amino optionally substituted by one or two C.sub.1-4 alkyl groups, C.sub.1-5 alkanoylamino, C.sub.5-7 cycloalkyloxy or C.sub.5-7 cycloalkyl. C.sub.1-4 alkyl groups in R.sub.7.sup.1 may be methyl, ethyl, n- or iso-propyl, n-, iso-, sec-, or tert-butyl. C.sub.5-7 cycloalkyl groups in R.sub.7.sup.1 may be cyclopentyl, cyclohexyl or cycloheptyl. R.sub.4 is preferably C.sub.5-7 cycloalkyl or C.sub.1-4 alkyl.
When Y is N:
Examples of R.sub.5, when C.sub.1-6 alkyl, include methyl, ethyl and n- and iso-propyl. Preferably such R.sub.5 is methyl.
A sub-group of R.sub.5, when C.sub.1-6 alkyl substituted by halogen is C.sub.1-6 alkyl substituted by chloro or bromo. Examples thereof include methyl or ethyl terminally substituted by chloro or bromo.
Examples of R.sub.5, when C.sub.1-6 alkyl substituted by hydroxy, include methyl or ethyl terminally substituted by hydroxy.
A sub-group of R.sub.5, when C.sub.1-6 alkyl substituted by alkoxy is C.sub.1-6 alkyl substituted by methoxy or ethoxy. Examples thereof include methyl or ethyl terminally substituted by methoxy or ethoxy.
A sub-group of R.sub.5, when C.sub.1-6 alkyl substituted by C.sub.1-6 alkoxycarbonyl is C.sub.1-6 alkyl substituted by methoxycarbonyl or ethoxycarbonyl. Examples thereof include methyl or ethyl terminally substituted by methoxycarbonyl or ethoxycarbonyl.
Examples of R.sub.5, when C.sub.1-6 alkyl substituted by carboxy include methyl or ethyl terminally substituted by carboxy.
Examples of R.sub.5 when alkyl substituted by amino optionally substituted by one or two independent C.sub.1-6 alkyl groups include a group (CH.sub.2).sub.r NR.sub.a R.sub.b where r is 1 to 6, and R.sub.a and R.sub.b are each independently hydrogen or C.sub.1-6 alkyl. Examples of r include 1 and 2, in particular 1. Preferably R.sub.a and R.sub.b are each independently selected from hydrogen and methyl. Examples of R.sub.5, when C.sub.2-6 alkenyl include vinyl, prop-1-enyl, prop-2-enyl, 1-methylvinyl, but-1-enyl, but-2-enyl, but-3-enyl, 1-methylenepropyl, or 1-methylprop-2-enyl, in both their E and Z forms where stereoisomerism exists.
Examples of R.sub.5 when amino optionally substituted as hereinbefore defined include amino optionally substituted by a C.sub.1-4 alkyl group as described for R.sub.7.sup.1, an allyl or trichloroacetyl group or by a phenyl group optionally substituted by one methyl, methoxy or chloro group or atom, in particular amino, methylamino, and phenylamino optionally substituted in the phenyl ring by one methyl, methoxy or chloro group or atom.
Examples of R.sub.5 when aryl include phenyl and naphtnyl, of which phenyl is preferred.
A sub-group of R.sub.5 heteroaryl or heteroaryl in a Z moiety when NR is 5- or 6-memberea monocyclic or 9- or 10-membered bicyclic heteroaryl of which 5- or 6-membered monocyclic heteroaryl is preferred. In addition, 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heteroaryl preferably contains one, two or three heteroatoms which are selected from the class of oxygen, nitrogen and sulphur and which, in the case of there being more than one heteroatom, are the same or different.
Examples of 5- or 6-membered monocyclic heteroaryl containing one, two or three heteroatoms which are selected from the class of oxygen, nitrogen and sulphur include furyl, thienyl, pyrryl, oxazolyl, thiazolyl, imidazolyl and thiadiazolyl, and pyridyl, pyridazyl, pyrimidyl, pyrazyl and triazyl. Preferred examples of such groups include furanyl, thienyl, pyrryl and pyridyl, in particular 2- and 3-furyl, 2- and 3-pyrryl, 2- and 3-thienyl, and 2-, 3- and 4-pyridyl.
Examples of 9- or 10-membered bicyclic heteroaryl containing one, two or three heteroatoms which are selected from the class of oxygen, nitrogen and sulphur include benzofuranyl, benzothienyl, indolyl and indazolyl, quinolyl and isoquinolyl, and quinazonyl. Preferred examples of such groups include 2- and 3-benzofuryl, 2- and 3-benzothienyl, and 2- and 3-indolyl, and 2- and 3-quinolyl.
Preferably, the number of groups or atoms for optional substitution of aryl or heteroaryl is one, two, three or four.
Preferred examples of the groups or atoms for optional substitution of aryl or heteroaryl include methyl, methoxy, hydroxy, bromo, chloro, fluoro, nitro or cyano.
A sub-group of R.sub.5 is phenyl or naphthyl or a 5- or 6-membered monocyclic or a 9- or 10-membered bicyclic heteroaryl, the phenyl, naphthyl or heteroaryl group being optionally substituted by one, two, three or four groups or atoms selected from the class of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen, (such as chloro, bromo or, in particular, fluoro), trifluoromethyl, nitro or cyano.
A preferred subgroup of phenyl optionally substituted as hereinbefore defined is phenyl, 4-substituted phenyl, 3-substituted phenyl, 3,4-disubstituted phenyl and 3,4,5-trisubstituted phenyl.
A preferred sub-group of 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heteroaryl optionally substituted as hereinbefore defined is unsubstituted or mono-substituted 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heteroaryl, in particular unsubstituted 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heteroaryl.
R.sub.5 and R.sub.6, when together are --CH.sub.2 --(CH.sub.2).sub.n --Z--(CH.sub.2).sub.m -- as defined the resulting radical substituting the penzopyran in the 4-position is preferably either pyrrolidonyl or piperidonyl.
When Z is other than CH.sub.2, m is often 0 or 1 and n is often 0 or 1. Suitable examples of R when Z is NR include hydrogen, methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl, benzyl, phenylcarbonyl or benzylcarbonyl optionally substituted in the phenyl ring by methyl, methoxy, chloro or bromo; furylcarbonyl, thienylcarbonyl, pyrrolylcarbonyl or indolylcarbonyl. Preferably R is hydrogen, methyl, n-butyl, acetyl, benzyl, benzylcarbonyl, phenylcarbonyl or furylcarbonyl. Most preferably R is methyl.
Preferred examples of R.sub.5 and R.sub.6 are R.sub.5 methyl and R.sub.6 hydrogen and R.sub.5 and R.sub.6 together are C.sub.3 or C.sub.4 polymethylene.
When Y is CH, R.sub.6 is preferably hydrogen and R.sub.5 is NR.sub.8 R.sub.9. Examples of R.sub.8 and R.sub.9, include hydrogen (for R.sub.8), methyl, ethyl, n- and iso-propyl, and n-, iso-, sec- and t-butyl, C.sub.4 or C.sub.5 polymethylene or R.sub.8 together with R.sub.6 is --(CH.sub.2).sub.2 -- or (CH.sub.2).sub.3 --, and R.sub.9 is hydrogen or an alkyl group as described above. Preferably R.sub.8 and R.sub.9 are each methyl or R.sub.6 CHCXNR.sub.8 R.sub.9 forms a pyrrolidone or piperidone ring and R.sub.9 is methyl.
Preferably, X is oxygen.
Examples of a pharmaceutically acceptable salt of a compound of formula (I), when the compound contains a salifiable group which is an optionally substituted amino group, include acid addition salts such as the hydrochloride and hydrobromide salts. Such a salifiable group may be within an R.sub.4 or R.sub.5 group. A carboxy group within R.sub.5 may also be salified to form metal salts, such as alkali metal salts, or optionally substituted ammonium salts.
The compounds of formula (I) may also exist as hydrates and these are included wherever a compound of formula (I) or a salt thereof is herein referred to.
The compounds of formula (I), are asymmetric, and, therefore, can exist in the form of optical isomers. The present invention extends to all such isomers individually and as mixtures, such as racemates.
Examples of compounds of formula (I) include the compounds prepared in the Examples hereinafter.
The present invention also provides a process for the preparation of a compound of formula (I) or, when the compound of formula (I) contains a salifiable group, a pharmaceutically acceptable salt thereof, which comprises;
i) (When Y is N) acylating a compound of formula (II): ##STR3## wherein R.sub.4 ' is R.sub.4 or a group convertible thereto; R.sub.1 R.sub.2 and R.sub.3 are as hereinbefore defined, and R.sub.6.sup.1 is hydrogen or C.sub.1-6 alkyl, the R.sub.6.sup.1 NH group being trans to the R.sub.3 group,
a) with an acylating agent of formula (III):
b) with a compound of formula (IV)
ii) where, in the resultant compound of formula (I), Y is N and R.sub.5 and R.sub.6 are joined together, or Y is CH, reacting a compound of formula (V): ##STR4## wherein R.sub.4 ', R.sub.1 and R.sub.2 are as hereinbefore defined, with a compound of formula (VI):
In the process variant i) a) acylation of a compound of formula (II) with an acylating agent of formula (III), the leaving group L.sub.1 is a group that is displaceable by a primary or secondary amino nucleophile. Examples of such a group include C.sub.1-4 alkanoyloxy, and halogen, such as chloro and bromo. When the leaving group L.sub.1 is either of these examples, the acylating agent of formula (III) is either an acid anhydride or an acid halide. When it is an acid anhydride, it may be a mixed or simple anhydride. If it is a mixed anhydride, it may be prepared in situ from a carboxylic acid and an acid halide, although this is less preferred than using the halide itself.
In process variant i) a), when R.sub.5 in the desired compound of formula (I) is an R.sub.5 optionally substituted amino-substituted alkyl group as hereinbefore defined, it is preferred that R.sub.11 is a group convertible to the R.sub.5 substituted alkyl group as hereinbefore defined, in particular that it is C.sub.1-6 alkyl substituted by halo, especially bromo. The R.sub.11 halo substituent in the resultant compound of process variant i) a) may be converted to an R.sub.5 substituent which is amino optionally substituted as hereinbefore defined by a conventional amination reaction with ammonia or a corresponding alkyl- or dialkylamine.
Less favorably R.sub.11 may be C.sub.1-6 alkyl substituted by protected amino, protected C.sub.1-6 alkylamino or amino substituted by two independent C.sub.1-6 alkyl groups, it being necessary to protect the R.sub.11 amino function in process variant i) a).
When the acylating agent of formula (III) is an acid anhydride, the acylation of the compound of formula (II) may be carried out in the presence of an acid acceptor, such as sodium acetate, optionally using the anhydride as the solvent.
When the acylating agent of formula (III) is an acid halide, the acylation of the compound of formula (II) is, preferably, carried out in a non-aqueous medium, such as dichloromethane, in the presence of an acid acceptor, such as triethylamine, trimethylamine, pyridine, picoline or calcium, potassium or sodium carbonate.
When R.sub.3 in a compound of formula (II) is hydroxy, there is a risk of a side-reaction between the hydroxy group and the acylating agent of formula (III). However, the reaction may be carried out under controlled conditions such that only the R.sub.6.sup.1 YH- is acylated, for example, by using a C.sub.2-9 acyloxy group as the leaving group L.sub.1, in the acylating agent of formula (III) in the manner as previously described for an acid anhydride, and/or effecting the reaction at relatively low temperature, e.g. at below 10.degree. C. Alternatively R.sub.3 may be C.sub.1-7 acyloxy in a compound of formula (II), although less preferably if R.sub.3 in the resultant compound of formula (I) is to be hydroxy, and, after reaction with the acylating agent of formula (III), be converted into hydroxy, as described hereinafter.
When R.sub.9 is Q(CH.sub.2).sub.z where the variables are as hereinbefore defined, the leaving group Q is a group that is displaceable by a secondary amino nucleophile adjacent to a carbonyl function. A preferred example is chloro.
The cyclisation reaction when R.sub.11 is Q(CH.sub.2).sub.z where the variables are as hereinbefore defined is preferably carried out in an inert solvent such as dimethylformamide.
In process variant i) b), when R.sub.12 in a compound of formula (IV) is C.sub.1-6 alkyl, C.sub.1-6 alkanoyl optionally substituted as hereinbefore defined, or phenyl optionally substituted as hereinbefore defined, the reaction between the compounds of formulae (II) and (IV) is, preferably, carried out in a solvent, such as methylene chloride, at below room temperature, in particular below 10.degree. C.
When R.sub.12 is hydrogen, the reaction between the compounds of formulae (II) and (IV) is, preferably, carried out using a corresponding alkali metal cyanate or thiocyanate, for example that of sodium or potassium, in an optionally methanolic aqueous medium acidified with a mineral acid, such as dilute hydrochloric acid. A slightly elevated temperature such as 50.degree. to 90.degree. C. is apt.
In the process variant ii) when Y is N, reaction of a compound of formula (V) with a compound of formula (VI), it is particularly preferred that the reaction is carried out under basic conditions so as to facilitate the formation of the anion of the compound of formula (VI), for example, in the presence of sodium hydride.
In the process variant ii) when Y is CH, the reaction is preferably carried out in a solvent such as tetrahydrofuran at a temperature of -70.degree. C. to reflux, depending on the anion of the compound of formula (VI). The anion is generated by use of a base, such as lithium diisopropylamide.
An intermediate compound wherein R.sub.13 is CHR.sub.10 CO.sub.2 R.sub.15 may be converted to a compound of formula (I) wherein R.sub.7 is CH.sub.2 R.sub.10, by deesterification followed by decarboxylation.
Deesterification may be effected conventionally, the most appropriate method depending to some extent on the nature of the group R.sub.14 . However, basic reaction conditions will generally be applicable. The process conditions described hereinafter for the decarboxylation in the presence of base are in general suitable for this deesterification.
When R.sub.14 is, for example, a tert-butyl group, deesterification may also be effected conventionally in the presence of acid such as trifluoroacetic acid or aqueous hydrochloric acid. Reaction may be effected at ambient temperature or a slightly higher temperature.
When R.sub.14 is for example a benzyl group, deesterification may also be effected conventionally by hydrogenolysis, for example by transition-metal catalysed hydrogenation, such as that using palladium/charcoal.
The decarboxylation is conveniently effected by treatment with a moderately strong base optionally in an aqueous reaction medium. Examples of bases for the reaction include inorganic bases such as sodium hydroxide. Examples of reaction media include water, usually in admixture with a water-miscible solvent such that the compound is soluble therein. Examples include aqueous alcohols such as aqueous ethanol and aqueous polyethers such as aqueous dioxan. Reaction is conveniently effected at a moderately elevated temperature, such as 50.degree. to 150.degree. C., conveniently at the boiling point of the reaction medium.
Alternatively the decarboxylation may be effected by heating to a non-extreme temperature, for example 60.degree. to 150.degree. C. in an inert solvent, such as benzene, toluene or xylene, for example at solvent boiling point. Spontaneous decarboxylation may occur under the reaction conditions for the deesterification. Even where this is not the case, it is convenient to decarboxylate the CHR.sub.10 CO.sub.2 H compound in situ without isolation. It is especially convenient to carry out the conversion CHR.sub.10 CO.sub.2 R.sub.12 to CH.sub.2 R.sub.10 as a single-step one-pot process, by treatment with a moderately strong base optionally in an aqueous reaction medium. Suitable conditions are as hereinbefore described for decarboxylation.
The reaction of the compounds of formulae (II) with (III) or (IV) results in a compound of formula (I) wherein R.sub.3 is hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy, whereas the reaction of the compounds of formulae (V) and (VI) results in a compound of formula (I) wherein P.sub.3 is hydroxy. Examples of an optional conversion of R.sub.3 in a compound of formula (I) into another R.sub.3 are generally known in the art. For example, when R.sub.3 is hydroxy, it may be alkylated using an alkyl iodine in an inert solvent, such as toluene, in the presence of a base, such as potassium hydroxide, or it may be acylated using a carboxylic acid chloride or anhydride in a non-hydroxylic solvent in the presence of antacid acceptor. Alternatively, when R.sub.3 is C.sub.1-7 acyloxy or C.sub.1-6 alkoxy, it may be converted into hydroxy by conventional hydrolysis with, for example, dilute mineral acid.
Suitable conversions of R.sub.4 '/R.sub.4 include conventional alkylation or acylation of R.sub.7 when hydroxy or optionally monosubstituted amino. It is usually preferred, however, that such conversions are carried out at an earlier stage.
R.sub.4 ' may be cyano which may be converted to R.sub.4 when a substituted methyl group, by conventional methods as described in the Examples hereinafter, for example, reduction to give an aminomethyl group.
The optional thiation of the R.sub.6 --Y--CO--R.sub.5 group in a compound of formula (I) to give another compound of formula I, wherein X is sulphur, is, preferably, carried out with conventional thiation agents, such as hydrogen sulphide, phosporous pentasulphide and Lawesson's reagent (p-methoxyphenylthiophosphine sulphide dimer). The use of hydrogen sulphide and phosporous pentasulphide may lead to side-reactions and, therefore, the use of Lawesson's reagent is preferred.
The thiation reaction conditions are conventional for the thiation agent employed. For example, the use of hydrogen sulphide is, preferably, acid catalysed by, for example, hydrogen chloride in a polar solvent, such as acetic acid or ethanol. The preferred use of Lawesson's reagent is, preferably, carried out under reflux in a dry solvent, such as toluene or methylene chloride.
The optional formation of a pharmaceutically acceptable salt, when the resulting compound of formula (I) contains a salifiable group, may be carried out conventionally.
A compound of formula (II) wherein R.sub.3 is hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy may be prepared by reacting a compound of formula (V), as hereinbefore defined, with a compound of formula (VII):
The resulting compound of formula (II) may be removed from the reaction mixture by removal of the solvent, for example, by evaporation under reduced pressure. Any epoxide impurity may be removed conventionally, for example by chromatography.
The optional conversion of the hydroxy group for R.sub.3 in the resulting compound of formula (II) into a C.sub.1-6 alkoxy or C.sub.1-7 acyloxy group may be carried out as described hereinbefore in relation to the corresponding conversion of R.sub.3 in a compound of formula (I).
A compound of formula (II) wherein R.sub.3 is hydrogen may be prepared by known methods, for example as described in Khim. Geterot. Soed 5(3), 434, 1969.
A compound of formula (V) may be prepared by reacting a compound of formula (VIII): ##STR5## wherein R.sub.1 and R.sub.2 are as hereinbefore defined, the bromine atom being trans to the hydroxy group, with a base, such as potassium hydroxide, in a solvent, such as ether or aqueous dioxan.
A compound of formula (VIII) may be prepared by reacting a compound of formula (IX): ##STR6## wherein R.sub.1 and R.sub.2 are as hereinbefore defined, with N-bromosuccinimide in a solvent, such as aqueous dimethyl sulphoxide.
A compound of formula (IX) may be prepared in accordance with analogous processes to those described in the aforementioned European Patent publications, i.e. by the process depicted below: ##STR7## (a) Reflux; acetone; K.sub.2 CO.sub.3 /KI; or a phase transfer catalytic method with optional sonification;
As mentioned previously, some of the compounds of formula (I) may exist in optionally active forms, and the processes of the present invention produce mixtures of such forms. The individual enantiomers may be resolved by conventional methods.
It is preferred that the compounds of formula (I) are isolated in pharmaceutically acceptable form.
The intermediates of formulae (II) represent part of the present invention. The intermediates of formulae (III), (IV), (V), (VI), (VII), (VIII) and (IX) are known or may be prepared in accordance with an appropriate known process.
As mentioned previously, the compounds of formula (I) have been found to have blood-pressure lowering activity. They are therefore useful in the treatment of hypertension. They are also believed to be of potential use in the treatment of other disorders hereinbefore referred to.
The present invention accordingly provides a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In particular, the present invention provides an anti-hypertensive pharmaceutical composition which comprises an anti-hypertensive effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration for patients suffering from heart failure. Other alternative modes of administration include sublingual or transdermal administration. A composition may be in the form of spray, aerosol or other conventional method of inhalation, for treating respiratory tract disorders.
The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.
Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.
The present invention further provides a method of prophylaxis or treatment of hypertension in mammals including man, which comprises administering to the suffering mammal an anti-hypertensive effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
An effective amount will depend on the relative efficacy of the compounds of the present invention, the severity of the hypertension being treated and the weight of the sufferer. However, a unit dose form of a composition of the invention may contain from 1 to 100 mg of a compound of the invention and more usually from 1 to 50 mg, for example 1 to 25 mg such as 1, 2, 5, 10, 15 or 20 mg. Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day, in a manner such that the daily dose is from 1 to 200 mg for a 70 kg human adult and more particularly from 1 to 100 mg.
No toxicological effects are indicated at the aforementioned dosage ranges.
The present invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis of hypertension.
The following descriptions relate to the preparation of intermediates and the following example relates to the preparation of a compound of formula (I).
All temperatures therein are in .degree.C.
US Referenced Citations (16)
Foreign Referenced Citations (9)
| Number |
Date |
Country |
| 0076075 |
Apr 1983 |
EPX |
| 0095316 |
Nov 1983 |
EPX |
| 0218373 |
Apr 1987 |
EPX |
| 183551 |
Jul 1978 |
NZX |
| 204297 |
Feb 1986 |
NZX |
| 213468 |
Apr 1986 |
NZX |
| 201984 |
Sep 1986 |
NZX |
| 208169 |
Nov 1986 |
NZX |
| 208170 |
Nov 1986 |
NZX |
Non-Patent Literature Citations (3)
| Entry |
| Evans, et al.; Journal of Medicinal Chemistry, (1983), vol. 26, pp. 1582-1589. |
| Evans, et al.; Journal of Medicinal Chemistry, (1984), vol. 27, pp. 1127-1131. |
| Ashwood, et al.; Journal of Medicinal Chemistry, (1986), vol. 29, pp. 2194-2201. |
Divisions (1)
|
Number |
Date |
Country |
| Parent |
45626 |
May 1987 |
|
Patent Grant
5075460
